Meeting
2021 Gastrointestinal Cancers Symposium
Serial cell-free DNA (cfDNA) sampling in advanced pancreatic ductal adenocarcinoma (PDAC) patients may predict therapeutic outcome.
Authors
Gehan Botrus
Mayo Clinic Arizona, Phoenix, AZ
Gehan Botrus , Yu Fu , Mohamad Bassam Sonbol , Leylah Drusbosky , Daniel H. Ahn , Mitesh J. Borad , Jason S. Starr , Jeremy Clifton Jones , Puneet Raman , Kabir Mody , Tanios S. Bekaii-Saab
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Pancreatic Cancer
Track
Pancreatic Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 423)
DOI
10.1200/JCO.2021.39.3_suppl.423
Abstract #
423
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.
First Author: Noura J. Choudhury
Poster
2021 ASCO Annual Meeting
Comprehensive molecular profiling of advanced cancers in a real-world setting using an ultrasensitive amplicon-based next-generation sequencing (NGS) liquid biopsy assay.
First Author: Jonathan Poh
Poster
2019 Genitourinary Cancers Symposium
Plasma cell-free DNA-based prognosis in metastatic hormone sensitive prostate cancer.
First Author: Manish Kohli
Poster
2015 Gastrointestinal Cancers Symposium
Next-generation sequencing (NGS) to identify potential therapeutic targets in advanced pancreatic cancer.
First Author: Madappa N. Kundranda